Ad comm meeting approaches for Durata drug

Anti-Infective Drugs Advisory Committee meets on Monday to review Durata Therapeutics' (DRTX) antibacterial Dalvance (dalbavancin) NDA.

PDUFA date is May 26.

Consensus total revenue estimates for 2014 and 2015 are $16.3M and $67.2M, respectively.

Meeting materials.

Comments (1)
  • GrowthGeek
    , contributor
    Comments (3095) | Send Message
    Wow, look at the difference in revenue projections from 2014 to 2015 and yet the stock price hasn't moved all that much. Look for DRTX to soar next week after Dalba passes the AdCom with flying colors.
    27 Mar 2014, 11:43 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs